Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens.
Journal: Open forum infectious diseases
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Castagna A, Marcon I, Du F, et al. (2026). "Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens.". Open forum infectious diseases. https://doi.org/10.1093/ofid/ofag487